Severe asthma (SA) afflicts a heterogeneous group of asthma patients who exhibit poor
responses to traditional asthma medications. SA patients likely represent 5–10% of all …

This review focuses on recent clinical and translational discoveries in severe and
uncontrolled asthma that now enable phenotyping and personalized therapies in these …

Severe asthma is defined by the high treatment requirements to partly or fully control the
clinical manifestations of disease. It remains a problem worldwide with a large burden for …

The mechanisms behind the development of severe asthma are poorly understood.
However, these patients disproportionately consume healthcare resources related to …

Although different phenotypes of severe asthma can be identified, all are characterized by
common symptoms. Due to their heterogeneity, they exhibit differences in pathogenesis …

Objective Severe asthma can be classified into phenotypes and endotypes, which may
inform clinicians about inflammatory pathways leading to disease and ultimately guide …

Severe asthma is a heterogeneous disease encompassing different phenotypes and
endotypes. Although patients with severe asthma constitute a small proportion of the total …

Severe asthmatics often exhibit poor control despite high doses of inhaled corticosteroids
with or without systemic corticosteroids and suffer from persistent symptoms and/or recurrent …

The term asthma encompasses a disease spectrum with mild to very severe disease
phenotypes whose traditional common characteristic is reversible airflow limitation. Unlike …

Corticosteroids are broadly active and potent anti‐inflammatory agents that, despite the
introduction of biologics, remain as the mainstay therapy for many chronic inflammatory …